The therapeutic value of monoclonal antibodies directed against immunogenic tumor glycoproteins

Journal of Cancer

Volumn 1, Issue 1, 2010, Pages 209-222

  Arlen, Myron ^a,b   Arlen, Philip ^a,b   Tsang, Al ^a,b   Wang, XuePing ^a,b   Gupta, Rishab ^a,b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b Med Univ of South Carolina   (United States)

Author keywords

ADCC; Apoptosis; Chimeric antibodies; Hybridomas; Monoclonal antibodies; Tumor specific antigens (TSA)

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; GLYCOPROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; LIPOCORTIN 5; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 31.1; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 6; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; BYSTANDER EFFECT; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL MEMBRANE; CELL POPULATION; CELL VIABILITY; CHIMERA; CHO CELL; CLINICAL TRIAL (TOPIC); COLON CANCER; CYTOTOXICITY; DIAGNOSTIC TEST; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE TARGETING; GOOD MANUFACTURING PRACTICE; HUMAN; HYBRIDOMA; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; NEOPLASM; NONHUMAN; PANCREAS CANCER; POLYMORPHONUCLEAR CELL; PROSTATE CANCER; PROTEIN BINDING; REVIEW; SENSITIVITY AND SPECIFICITY; SERUM; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

EID: 83455259113     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.1.209     Document Type: Review

References (24)

1. Liu W.M., Fowler D.W., Smith P and Dalgleish A.G. Pre-Treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumors by promoting adaptive immune responses. Br. J. Cancer, 2010;102: 115-123.
2. Ramakrishnan R., Assudani D., Nagaraj S., Hunter T., Cho H., et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during Cancer Immunotherapy in mice. J Clin Invest. 2010,120: 1111-1124.
3. Qu CF, Song EY, Li Y, Rizvi SMA, Raja C, Smith R, Morgenstern A, Apostolidis C, Allen BJ. Preclinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clinical & Experimental Metastasis. 2005;22: 575-586.
4. Hollinshead A., Elias G., Arlen M, et al. Specific Active Im-munotherapy in patients with adenocarcinoma of the colon utilizing tumor associated antigens (TAA). Cancer 1985;56: 480-489.
5. Arlen M. Escape Mechanisms employed by tumor cells to allow for growth, invasion and metastasis; In Chemoimmunosensitization of Resistant Tumor Cells to Cell Death by Apoptosis (text). Bonavida 2006;:243-261.
6. Arlen M, Tsang K.W. The Nature of the Monoclonal Antibodies derived from Immunogenic membrane antigen of colon carcinoma origin. J. Tumor Marker Oncology 1990;5: 313-319.
7. Jazirehi A.R., Bonavida B. Cellular and Molecular Signal Trans-duction Pathways Modulated by Rituximab in Non Hodgkins Lymphoma. Implications in Chemotherapy Sensitization. Oncogene 2005;24: 2121-2143.
8. Catimel B. et al Purification and characterization of a novel restricted antigen expressed by normal and transformed human colonic epithelium. J. Biol. Chem. 1999;271: 25664-25670.
9. Morrone S. Annexin V. Cytometry CD Rom Series V.4. USA: Purdue Cytometry. 1998.
10. Francis RJ, Sharma SK, Springer C, et al. A phase I trial of anti-body directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumors. Br. J. Cancer 2002;87:600-607.
11. Schuster M, Umana P, Ferrara C, Brunker P, Gerdes C, et al. Improved Effector Functions of a Therapeutic Monoclonal Lewis Y-Specific Antibody by Glycoform Engineering. Cancer Research 2005;65: 7934-7941.
12. Durrant L.G, Robbins R.A, Baldwin R.W. Flow Cytometric Screening of Monoclonal Antibodies for Drug or Toxin Targeting to Human Cancer. J. Nat Cancer Institute. 1989;81:688-695.
13. Tang Y, Lou J, Alpaugh RK., Robinson MK, Marks JD, and Weiner LM. Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen. J. Immunol. 2007;179: 2815-2832.
14. Tsang K.Y., Finch M.D., Primus F.J., and Schlom J. Human re-combinant interleudin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells. Cancer Immunol Immunother. 1991;34: 9-16.
15. Liu A.Y., Robinson R.R., Hellstrom K.E., Murray E.D., Chang C.P, and Hellestrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc. Nat. Acad. Sci. USA 1987;84: 3439-3443.
16. Fagerberg J., Hjelm A.L, Ragnhammar P, Frodin J.E, Wigzell H., Mellstedt H. Tumor regression in monoclonal antigody treated patients correlates with the presence of anti-idiotype reactive Tlymphocytes. Cancer Research 1995;55:1824-1827.
17. Krotkiewski H., Gronbergl G., Krotkiewska B., Nilssonll B and Svensson S. The Carbohydrate Structures of a Mouse Monoclonal IgG Antibody OKT3. J. Biol. Chem. 1990;265: 2019-2021.
18. Mellstedt H, Frodin JE, Massucci G. Clinical status of monoc-lonal antibodies in the treatment of colorectal carcinoma. Oncology 1989;3: 25-31.
19. Reitmuller G, et al. Randomized trial of mAb for adjuvant therapy of resected Dukes'C colorectal cancinoma. The Lancet 1994; 343:1177-1183.
20. Wu X, Fan Z, Masui H, Rosen N. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human. J Clin Invest. 1995; 95(4): 1897-1905.
21. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2+ breast cancer. N Engl J Med. 2005; 353: 1673-1684.
22. Muhsin M., Graham J, and Kirkpatrick P. Bevacizumab. Nature Reviews Drug Discovery 2004;3: 995-996.
23. Lipscomb M.L., Palomarea L.A., Hernandez V., Ramirez O.T., and Kompala D.S. Effect of Production Method and Gene Amplification on the Glycosylation Pattern of a Secreted Reporter Protein in CHO Cells. Biotechnol. Prog. 2005;21:40-49.
24. Clynes, R.A, Tower T, Dresta G and Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 2000;6: 443-446.